# High Flow Nasal Oxygenation in Transcatheter Aortic Valve Replacement Procedures. TAVR-Highflow II

Study · id `cardio:ct-nct07059728` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07059728](<https://clinicaltrials.gov/study/NCT07059728>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07059728

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 452 participants.

## Technical summary

Registry record NCT07059728. Randomized; no masking; primary purpose supportive care. Start 2027-01-01 (anticipated); primary completion 2028-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose supportive care
- Phase: Not applicable
- Enrolled: 452 participants (planned count; ClinicalTrials.gov record NCT07059728, source copy `cardio:ctgov-nct07059728-2026-09-18`, retrieved 2026-10-26)
- Planned start: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT07059728, source copy `cardio:ctgov-nct07059728-2026-09-18`, retrieved 2026-10-26)
- Primary completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT07059728, source copy `cardio:ctgov-nct07059728-2026-09-18`, retrieved 2026-10-26)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07059728, source copy `cardio:ctgov-nct07059728-2026-09-18`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT07059728, source copy `cardio:ctgov-nct07059728-2026-09-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07059728-2026-09-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: High Flow Nasal Oxygenation in Transcatheter Aortic Valve Replacement Procedures. TAVR-Highflow II
- Condition: Aortic Stenosis Treated With TAVI
- Condition: Sedation; Aged; Hemodynamics
- Intervention (Device): Oxygen therapy during sedation provided via high nasal cannulae (60L/min at 60% FiO2)
- Intervention (Device): Oxygen therapy during sedation delivered via nasal cannulae at 5L/min
- Lead sponsor: Hospital Clinic of Barcelona
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Hospital Clinic of Barcelona (`cardio:org-hospital-clinic-of-barcelona`)

## Provenance

Content hash: 722767c7be80ae862acc45323218cc06d1d7dd85a3b0effaeb98f5310e008532
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
